GenSight Biologics: Cash Reserves Drop to €1.7M by End of June, Down 47% in Three Months
GenSight Biologics reported a critical 47% decrease in cash reserves over three months, falling to €1.7M as of June 30, 2026, from €3.2M at the end of March. The gene therapy lab now relies on the unpredictable revenue from its early access programs to fund its 2026 operations, while it accelerates the preparation of its Phase III clinical trial for the treatment of Leber's Hereditary Optic Neuropathy (LHON).
Accelerated Cash Burn Despite Early Access Revenues
GenSight Biologics' cash reserves decreased by €1.5M over three months, primarily due to the management of early access programs for GS010/Lumevoq and the preparation for the Phase III Recover trial. The group, however, collected €6.8M in cash during the first half of 2026 from these programs, including €4.3M in the second quarter. These receipts include the payment for the first patient treated under the Israeli named patient program. However, the financial stability of the group depends on a largely unpredictable variable. GenSight warned that treatments conducted in 2026 under these programs would remain irregular in terms of timing and amounts. Furthermore, the group will be required to pay a rebate of between 25% and 35% on revenues from the French early access program, due in November 2027.
Acceleration of Manufacturing and Clinical Investments
GenSight has strengthened its organization by adding staff in the Quality and Chemistry-Manufacturing-Controls (CMC) departments during the period. The lab also plans to bolster its clinical team in the second half of 2026. These investments accompany the finalization of the technology transfer for manufacturing GS010/Lumevoq with Catalent, its contract manufacturing partner. The engineering trial was launched in June, and the group expects to confirm the success of the technology transfer during the summer of 2026. Following this confirmation, GenSight will begin manufacturing the batches needed to supply both the Phase III Recover trial and its early access programs. The lab currently has over 60 vials in inventory, which it estimates will be sufficient to treat patients until the end of June 2027.
Early Access Revenues Expected to Cover 2026 Operational Expenses, Excluding RECOVER
GenSight indicated that the aggregate revenues expected from the early access programs during 2026 should be sufficient to cover the group's operating expenses for the year, excluding the costs associated with the Phase III Recover clinical trial, which include related manufacturing costs. The group specified its inability to predict the exact timing of treatments and related payments under its various early access programs over the next year. Additionally, GenSight negotiated with Heights Capital a deferral of the amortization of its convertible bond scheduled for June 2026 until the end of December 2027, thereby relieving the immediate need for liquidity. The group will publish its accounts for the first half of 2026 on September 29, 2026.
